Research and Markets has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2016" drug pipelines to their offering.
Chemotherapy Induced Anemia Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.
Chemotherapy Induced Anemia pipeline therapeutics constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2, 3 and 7 respectively.
Our latest report Chemotherapy Induced Anemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.
Key Topics Covered:
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/2g4lww/chemotherapy
Related Topics: Hematological Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006051/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.